Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/
Accepted 2025-01-22 00:00:00 ET · period of report 2025-01-19 · accession 0000950170-25-007545 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-22 | 2025-01-19 | HRTX | Collard Craig A | CEO, Dir | M - OptEx | — | +13.8K | 314.9K | +5% | — |
| D | 2025-01-22 | 2025-01-19 | HRTX | Collard Craig A | CEO, Dir | M - OptEx | $0.00 | -13.8K | 165.6K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-19 | M | A | 13,797 | — | 314,867 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. (F2) Includes 10,683 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2024. |
| 2 | Derivative | Restricted Stock Units | 2025-01-19 | M | D | 13,797 | $0.00 | 165,562 | D | $0.00 · — to — | 13,797 Common Stock | (F3) The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). |